What’s been published/presented?
Click on the links below to view publications of interest to you. You can also search our publications database by author, keyword(s), date of publication, journal or other parameters. Or, download our bibliography.
Platform Technology
Biomarker discovery for colon cancer using a 761 gene RT-PCR assay
Kim M Clark-Langone*1, Jenny Y Wu1, Chithra Sangli1, Angela Chen1,James L Snable1, Anhthu Nguyen1, James R Hackett1,Joffre Baker1,Greg Yothers2, Chungyeul Kim2 and Maureen T Cronin1
BMC Genomics. 2007;
8(279):1471-2164-8-279.
Measurement of Gene Expression in Archival Paraffin-Embedded Tissues
M Cronin, M Pho, D Dutta, JC Stephans, S Shak, MC Kiefer, JM Esteban, JB Baker
Am J Pathol. 2004;
164(1):35-42.
Additional Oncotype DX Assay-Related Articles
Validation Study of a Quantitative Multigene Reverse Transcriptase–Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
Gray RG, Quirke P, Handley K, et al.
J Clin Oncol. 2011;
29(32):
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
R Simon
J Clin Oncol. 2005;
23(29):7332-7341.
Scientific Presentations, Posters & Abstracts
2012 ASCO - GI - San Francisco, CA
Abstract #398
Effect of Oncotype DX Colon Cancer Test Results on Treatment Recommendations in Patients with Stage II Colon Cancer: Preliminary Results
Cartwright T, Chao C, Lopatin M, Bentley T, Broder M, Chang E
2012;
2011 ASCO - Chicago, IL
Abstract #3518
Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581.
A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. Frankel, K. Clark-Langone, C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg, N. N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli, Cancer and Leukemia Group B; University of California, San Francisco, San Francisco, CA; Duke University, Durham, NC; Genomic Health, Redwood City, CA; Cancer and Leukemia Group B, Chicago, IL; The Ohio State University, Columbus, OH; University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Pennsylvania, Philadelphia, PA; The University of Chicago, Chicago, IL; Brigham and Women's Hospital, Boston, MA
2011;
2011 ASCO - GI - San Francisco, CA
Abstract #403
Assay result variability during determination of mismatch repair deficiency status using immunohistochemistry: A transatlantic comparative study.
G. Hutchins, K. Handley, F. L. Baehner, M. Lopatin, H. Yaziji, M. Lee, M. T. Seymour, D. J. Kerr, R. G. Gray, P. Quirke; University of Leeds, Leeds, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University of California, San Francisco, San Francisco, CA; Genomic Health, Redwood City, CA; Vitro Molecular Laboratories, Miami, FL; CRUK Cancer Centre, University of Leeds, Leeds, United Kingdom; Sidra Medical and Research Center, Doha, Qatar
2011;
Abstract #491
Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: Impact on quality-adjusted life expectancy and costs.
N. J. Meropol, G. H. Lyman, R. Chien, J. C. Hornberger; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Duke University, Durham, NC; Cedar Associates LLC, Menlo Park, CA
2011;
Abstract #526
Reproducibility of colon tumor grade and relationship to recurrence in the context of clinical, pathologic, and genomic tumor features in 504 patients with stage II colon cancer treated with surgery alone at the Cleveland Clinic.
I. C. Lavery, F. L. Baehner, M. Lopatin, G. Iezza, C. Millward, K. Clark-Langone, M. Lee; Cleveland Clinic, Cleveland, OH; University of California, San Francisco, San Francisco, CA; Genomic Health, Redwood City, CA
2011;
2010 ASCO - Chicago, IL
Abstract #3503
Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score.
M. J. O'Connell, I. C. Lavery, R. G. Gray, P. Quirke, D. J. Kerr, M. Lopatin, G. A. Yothers, M. Lee, K. Clark-Langone, N. Wolmark; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Cleveland Clinic Foundation, Cleveland, OH; University of Birmingham, Birmingham, United Kingdom; University of Leeds, Leeds, United Kingdom; Sidra Medical and Research Center, Doha, Qatar; Genomic Health, Redwood City, CA; National Surgical Adjuvant Breast and Bowel Project Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA
2010;
2009 ASCO Breast Meeting San Francisco, CA
Abstract #4000
A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in 4 large studies and results of the independent, prospectively-designed QUASAR validation study
D Kerr, R Gray, P Quirke, et al ASCO 2009
2009;
2008 ASCO Gastrointestinal Cancers Symposium
Abstract #302
Relationship between tumor gene expression and recurrence in an observational cohort of patients with stage II/III colon cancer treated with surgery only: Quantitative RT-PCR assay of 375 genes in fixed paraffin-embedded (FPE) tissue
I Lavery, J Hammel, JW Cowens, et al Proc ASCO Gastrointestinal Cancers Symposium 2008.
2008;
2006 ASCO
Abstract #3518
Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue
MJ O’Connell, S Paik, G Yothers, et al Proc ASCO 2006.
2006;